Tobias Monschein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tobias Monschein has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Berger
Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria
9 shared publications - Tobias Zrzavy
Department of Neurology Medical University of Vienna Vienna Austria
9 shared publications - Paulus Stefan Rommer
Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria
8 shared publications - Barbara Kornek
Department of Neurology, Medical University of Vienna, Austria
6 shared publications Fritz Leutmezer
6 shared publications- Gabriel Bsteh
Department of Neurology, Medical University of Vienna, Vienna, Austria
6 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (1)
Association of treatment decision with personality, coping strategies and impulsivity in patients with multiple sclerosis
Introduction: Shared decision-making is advocated in treating patients with multiple sclerosis (pwMS), enabled by the wide range of disease-modifying treatments (DMTs). However, the role of psychological characteristics in treatment decisions remains understudied. Methods: In a prospective study, pwMS completed the Big Five Trait inventory, UPPS Impulsive Behaviour Scale and Brief COPE at treatment initiation. Associations between choosing high-efficacy DMTs (H-DMT; natalizumab, anti-CD20 monoclonal antibodies) versus low/moderate-efficacy DMTs were analysed using logistic regression, for each dimension separately, then in a multidimensional model. Propensity scoring adjusted for MS-associated determinants of DMT choice (sex, age, disease duration, prior DMT, relapse in previous year, Expanded Disability Status Scale [EDSS]). Results: Of 148 pwMS (75.7% female, age 36.5 years [SD 9], EDSS 1.0 [IQR, 0–2]) 53.4% initiated H-DMT. Higher active coping (adjusted odds ratio [aOR] 1.59, p = 0.024) and openness (aOR 1.48, p = 0.046) were significantly associated with H-DMT choice, with trends for extraversion (aOR 1.38, p = 0.097), supportive coping (aOR 1.42, p = 0.069), and higher perseverance (aOR 1.43, p = 0.068). In the multidimensional model, neuroticism demonstrated the most substantial association (aOR 2.17, p = 0.005). Conclusion: Personality structure, particularly neuroticism, active coping and openness may influence treatment decisions among pwMS.
- 13 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (1)
Open AccessAssociation of treatment decision with personality, coping strategies and impulsivity in patients with multiple sclerosis
Introduction: Shared decision-making is advocated in treating patients with multiple sclerosis (pwMS), enabled by the wide range of disease-modifying treatments (DMTs). However, the role of psychological characteristics in treatment decisions remains understudied. Methods: In a prospective study, pwMS completed the Big Five Trait inventory, UPPS Impulsive Behaviour Scale and Brief COPE at treatment initiation. Associations between choosing high-efficacy DMTs (H-DMT; natalizumab, anti-CD20 monoclonal antibodies) versus low/moderate-efficacy DMTs were analysed using logistic regression, for each dimension separately, then in a multidimensional model. Propensity scoring adjusted for MS-associated determinants of DMT choice (sex, age, disease duration, prior DMT, relapse in previous year, Expanded Disability Status Scale [EDSS]). Results: Of 148 pwMS (75.7% female, age 36.5 years [SD 9], EDSS 1.0 [IQR, 0–2]) 53.4% initiated H-DMT. Higher active coping (adjusted odds ratio [aOR] 1.59, p = 0.024) and openness (aOR 1.48, p = 0.046) were significantly associated with H-DMT choice, with trends for extraversion (aOR 1.38, p = 0.097), supportive coping (aOR 1.42, p = 0.069), and higher perseverance (aOR 1.43, p = 0.068). In the multidimensional model, neuroticism demonstrated the most substantial association (aOR 2.17, p = 0.005). Conclusion: Personality structure, particularly neuroticism, active coping and openness may influence treatment decisions among pwMS.
- Open Access
- 17 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70471
The Value of Oligoclonal Bands in Multiple Sclerosis Compared to Other Neurological Disorders: A Retrospective Data Analysis From an Austrian Tertiary Center
Background: Cerebrospinal fluid (CSF) analysis is key to diagnosing multiple sclerosis (MS). In particular, the presence of CSF‐specific oligoclonal bands (OCB) is examined alongside differential diagnostic aspects. This study aims to investigate the diagnostic value of OCB in MS compared to other neurological disorders. Methods: Patients who presented to the Department of Neurology of the Medical University of Vienna between January 1, 2004 and December 31, 2020, due to neurological complaints and underwent lumbar puncture (LP) for diagnostic purposes were included in this retrospective analysis. Exclusion criteria were incomplete laboratory data and/or a missing final diagnosis. Results: Of 5744 patients who underwent LP, 5225 were available for analysis. Of these, 745 (14.3%) were diagnosed with MS, whereby CSF‐specific OCB showed a sensitivity of 92.8% and a specificity of 90.4%. While the positive predictive value (PPV) was merely 61.5%, the negative predictive value (NPV) yielded 98.7%. In comparison, OCB displayed low sensitivity rates for most other neurological disease groups. Of note, neuroborreliosis ( n = 66) had a relatively high OCB positive rate of 70%, followed by CNS human immunodeficiency virus infections ( n = 32) with 62.5%. Conclusions: CSF‐specific OCB have a high sensitivity and specificity and a very high NPV for diagnosing MS. However, the PPV was lower in this cohort. These findings must be carefully considered when diagnosing MS and interpreting OCB, especially in the context of differential diagnostic workup.
- 17 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70471
Open AccessThe Value of Oligoclonal Bands in Multiple Sclerosis Compared to Other Neurological Disorders: A Retrospective Data Analysis From an Austrian Tertiary Center
Background: Cerebrospinal fluid (CSF) analysis is key to diagnosing multiple sclerosis (MS). In particular, the presence of CSF‐specific oligoclonal bands (OCB) is examined alongside differential diagnostic aspects. This study aims to investigate the diagnostic value of OCB in MS compared to other neurological disorders. Methods: Patients who presented to the Department of Neurology of the Medical University of Vienna between January 1, 2004 and December 31, 2020, due to neurological complaints and underwent lumbar puncture (LP) for diagnostic purposes were included in this retrospective analysis. Exclusion criteria were incomplete laboratory data and/or a missing final diagnosis. Results: Of 5744 patients who underwent LP, 5225 were available for analysis. Of these, 745 (14.3%) were diagnosed with MS, whereby CSF‐specific OCB showed a sensitivity of 92.8% and a specificity of 90.4%. While the positive predictive value (PPV) was merely 61.5%, the negative predictive value (NPV) yielded 98.7%. In comparison, OCB displayed low sensitivity rates for most other neurological disease groups. Of note, neuroborreliosis ( n = 66) had a relatively high OCB positive rate of 70%, followed by CNS human immunodeficiency virus infections ( n = 32) with 62.5%. Conclusions: CSF‐specific OCB have a high sensitivity and specificity and a very high NPV for diagnosing MS. However, the PPV was lower in this cohort. These findings must be carefully considered when diagnosing MS and interpreting OCB, especially in the context of differential diagnostic workup.
- Open Access
- 5 December 2025
- Published by MDPI AG in Clinical and Translational Neuroscience
- Vol. 9 (4) , 56
Promoting Brain Health: Report on Activities of the Bern Brain Health Working Group
Brain Health has become a global public health priority, driven mainly by the rapid aging of populations and the increasing burden of neurological and psychiatric disorders. This report presents the first activities of the Bern Brain Health Working Group, established to implement the Swiss Brain Health Plan (SBHP), published in 2023. The aim is to describe the development and initial outcomes of regional initiatives promoting Brain Health in Switzerland. Specifically, we outline the structure and objectives of the Bern Brain Health Consultation, the development process and conceptual framework of the Swiss Brain Health Questionnaire, and additional educational and research activities supporting the SBHP. By summarizing these first steps, this report provides a model for regional implementation of a national Brain Health strategy and contributes to building a foundation for broader national and international Brain Health efforts.
- 5 December 2025
- Published by MDPI AG in Clinical and Translational Neuroscience
- Vol. 9 (4) , 56
Open AccessPromoting Brain Health: Report on Activities of the Bern Brain Health Working Group
Brain Health has become a global public health priority, driven mainly by the rapid aging of populations and the increasing burden of neurological and psychiatric disorders. This report presents the first activities of the Bern Brain Health Working Group, established to implement the Swiss Brain Health Plan (SBHP), published in 2023. The aim is to describe the development and initial outcomes of regional initiatives promoting Brain Health in Switzerland. Specifically, we outline the structure and objectives of the Bern Brain Health Consultation, the development process and conceptual framework of the Swiss Brain Health Questionnaire, and additional educational and research activities supporting the SBHP. By summarizing these first steps, this report provides a model for regional implementation of a national Brain Health strategy and contributes to building a foundation for broader national and international Brain Health efforts.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214069
Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis
Progression independent of relapse activity (PIRA) is the main driver of disability accumulation in relapsing multiple sclerosis (RMS). Retinal layer atrophy measured by optical coherence tomography (OCT) reflects neuroaxonal damage and is associated with PIRA. However, it remains unclear whether this association is driven by subclinical inflammatory activity or reflects true progression independent of acute inflammation. Here, we aimed to investigate the relationship between retinal layer atrophy and progression independent of relapse and MRI activity (PIRMA) to clarify the impact of subclinical inflammatory activity. From an ongoing prospective observational study, patients with RMS meeting the following criteria were included: an OCT scan conducted 3-6 months after disease-modifying treatment (DMT) initiation (rebaseline) and at least one follow-up OCT after ≥12 months. Disability accrual was defined as a composite measure comprising worsening in either Expanded Disability Status, Timed 25-Foot Walk Test, 9-Hole Peg Test, or Symbol Digit Modalities Test using a roving baseline with a 6-month confirmation interval. PIRA was defined as disability accrual without relapse between roving baseline and confirmation. PIRMA was defined as PIRA that remained radiologically silent. We evaluated associations between PIRMA and thinning of the peripapillary retinal nerve fiber layer (pRNFL) and the macular ganglion cell plus inner plexiform layer (GCIPL) using multivariable mixed-effects linear regression models adjusted for relevant covariables (age, sex, disease duration, GCIPL/pRNFL at rebaseline, and moderate vs high-efficacy DMT). A total of 210 patients with RMS (mean age 30.5 years, SD 7.9; 74.1% female) were analyzed over a median observation period of 2.3 years (range 1-5.9 years). PIRMA was observed in 28 (13.3% overall, 41.8% of all disability accruals, 54.1% of PIRA) patients, while PIRA was encountered in 50 (23.8% overall, 77.2% of all disability accruals). Multivariable models revealed that PIRMA (vs no PIRMA) was associated with significantly more pronounced thinning of both GCIPL (0.72% per year, 95% CI 0.50-0.82, p < 0.001) and pRNFL (1.05% per year, 95% CI 0.89-1.18, p < 0.001). Our findings indicate that retinal atrophy is significantly linked with PIRMA, reinforcing its potential as a biomarker of MS-related neuroaxonal degeneration that occurs independently of acute focal inflammation.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214069
Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis
Progression independent of relapse activity (PIRA) is the main driver of disability accumulation in relapsing multiple sclerosis (RMS). Retinal layer atrophy measured by optical coherence tomography (OCT) reflects neuroaxonal damage and is associated with PIRA. However, it remains unclear whether this association is driven by subclinical inflammatory activity or reflects true progression independent of acute inflammation. Here, we aimed to investigate the relationship between retinal layer atrophy and progression independent of relapse and MRI activity (PIRMA) to clarify the impact of subclinical inflammatory activity. From an ongoing prospective observational study, patients with RMS meeting the following criteria were included: an OCT scan conducted 3-6 months after disease-modifying treatment (DMT) initiation (rebaseline) and at least one follow-up OCT after ≥12 months. Disability accrual was defined as a composite measure comprising worsening in either Expanded Disability Status, Timed 25-Foot Walk Test, 9-Hole Peg Test, or Symbol Digit Modalities Test using a roving baseline with a 6-month confirmation interval. PIRA was defined as disability accrual without relapse between roving baseline and confirmation. PIRMA was defined as PIRA that remained radiologically silent. We evaluated associations between PIRMA and thinning of the peripapillary retinal nerve fiber layer (pRNFL) and the macular ganglion cell plus inner plexiform layer (GCIPL) using multivariable mixed-effects linear regression models adjusted for relevant covariables (age, sex, disease duration, GCIPL/pRNFL at rebaseline, and moderate vs high-efficacy DMT). A total of 210 patients with RMS (mean age 30.5 years, SD 7.9; 74.1% female) were analyzed over a median observation period of 2.3 years (range 1-5.9 years). PIRMA was observed in 28 (13.3% overall, 41.8% of all disability accruals, 54.1% of PIRA) patients, while PIRA was encountered in 50 (23.8% overall, 77.2% of all disability accruals). Multivariable models revealed that PIRMA (vs no PIRMA) was associated with significantly more pronounced thinning of both GCIPL (0.72% per year, 95% CI 0.50-0.82, p < 0.001) and pRNFL (1.05% per year, 95% CI 0.89-1.18, p < 0.001). Our findings indicate that retinal atrophy is significantly linked with PIRMA, reinforcing its potential as a biomarker of MS-related neuroaxonal degeneration that occurs independently of acute focal inflammation.
- Open Access
- 19 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (10) , 1175-1186
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis
Background: Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers of axonal damage and astrocytic activation. The value of sNfL and GFAP in predicting retinal layer thinning remains underexplored. Objectives: To evaluate the association between sNfL and GFAP levels and retinal layer thinning. Methods: This prospective observational study included people with relapsing MS (pwMS) newly initiated on a disease-modifying therapy (DMT). Optical coherence tomography (OCT) scans were conducted 3–6 months after DMT initiation and at 12-month intervals measuring peripapillary retinal nerve fibre layer (pRNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness. sNfL and GFAP levels were measured at baseline and after 6 months (M6) using single-molecule array (Simoa ® ) technology. Results: A total of 116 pwMS (mean age 34.5 years [SD 8.6]), 73.3% female) were included. GFAP z-scores at M6 showed the strongest association with annualized loss of pRNFL (aLpRNFL: b = −0.24; 95% confidence interval [CI] −0.27, −0.21, p < 0.001) and GCIPL (aLGCIPL: b = −0.15; 95% CI: −0.18, −0.12, p < 0.001). Moreover, pwMS with low sNfL but high GFAP levels at M6 showed the most pronounced retinal layer thinning (aLpRNFL: −0.8%/year [1.1], aLGCIPL: −0.8%/year [0.9]; both p < 0.001). Conclusions: High GFAP levels – more than sNfL levels – are associated with retinal layer thinning in relapsing MS.
- 19 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (10) , 1175-1186
Open AccessSerum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis
Background: Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers of axonal damage and astrocytic activation. The value of sNfL and GFAP in predicting retinal layer thinning remains underexplored. Objectives: To evaluate the association between sNfL and GFAP levels and retinal layer thinning. Methods: This prospective observational study included people with relapsing MS (pwMS) newly initiated on a disease-modifying therapy (DMT). Optical coherence tomography (OCT) scans were conducted 3–6 months after DMT initiation and at 12-month intervals measuring peripapillary retinal nerve fibre layer (pRNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness. sNfL and GFAP levels were measured at baseline and after 6 months (M6) using single-molecule array (Simoa ® ) technology. Results: A total of 116 pwMS (mean age 34.5 years [SD 8.6]), 73.3% female) were included. GFAP z-scores at M6 showed the strongest association with annualized loss of pRNFL (aLpRNFL: b = −0.24; 95% confidence interval [CI] −0.27, −0.21, p < 0.001) and GCIPL (aLGCIPL: b = −0.15; 95% CI: −0.18, −0.12, p < 0.001). Moreover, pwMS with low sNfL but high GFAP levels at M6 showed the most pronounced retinal layer thinning (aLpRNFL: −0.8%/year [1.1], aLGCIPL: −0.8%/year [0.9]; both p < 0.001). Conclusions: High GFAP levels – more than sNfL levels – are associated with retinal layer thinning in relapsing MS.
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (3) , e200393
SARS-CoV-2 Vaccines and Multiple Sclerosis
The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.1-3 Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.4 In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.
- 1 May 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (3) , e200393
Open AccessSARS-CoV-2 Vaccines and Multiple Sclerosis
The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.1-3 Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.4 In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.
- Open Access
MuSic Moves—co-creating a music-supported exercise programme with and for people with multiple sclerosis: a bicentre participatory mixed methods study
Objectives To collaboratively develop a music-supported video-based exercise programme for people with multiple sclerosis (pwMS) with mild to severe disability. Design and setting We performed this participatory mixed methods study from 15 March 2022 to 22 July 2023 at two Austrian multiple sclerosis (MS) centres. Participants This research included 67 pwMS, of whom 18 pwMS (including two patient representatives and five MS support group leaders/members) and an additional three family members served as stakeholders. Six neurologists and six physiotherapists, each with >5 years of experience in treating pwMS were interviewed. Intervention Stakeholders actively participated as members of study advisory, project steering and research groups. Researcher-supported peer-to-peer focus groups and individual interviews, conducted in three stages, gathered information on musical preferences and exercise needs. We co-developed, co-evaluated and co-adapted the music-supported exercise programme with the stakeholders. Involvement levels were measured using the Participation Check and Patient Public Involvement (PPI) Assessment Survey, self-efficacy with the Unidimensional Self-Efficacy Scale for Multiple Sclerosis and emotional states with the Self-Assessment Manikin. Results We identified four themes through reflexive thematic analysis: (1) engagement; (2) ease; (3) autonomy; (4) musical meaning. Integration of qualitative and quantitative components highlighted the success of PPI activities: (a) 148 co-created, free videos are publicly available; (b) four videos provide expert interviews with general information, while 144 offer music-supported exercises tailored to pwMS with mild to severe disability; (c) patients found the videos relevant, feasible and usable in interviews and focus groups; (d) ‘easy’ category exercises (seated or lying) are suitable for severely affected pwMS; (e) stakeholders felt included, respected and heard, as shown by quantitative PPI assessments. Conclusions Stakeholders were essential in identifying key aspects, preferences and constraints early on. Their feedback on music and exercise shaped the project. This study transformed our approach to exercise for pwMS. Future studies are required to evaluate the programme’s efficacy. Trial registration number DRKS00027979.
Open AccessMuSic Moves—co-creating a music-supported exercise programme with and for people with multiple sclerosis: a bicentre participatory mixed methods study
Objectives To collaboratively develop a music-supported video-based exercise programme for people with multiple sclerosis (pwMS) with mild to severe disability. Design and setting We performed this participatory mixed methods study from 15 March 2022 to 22 July 2023 at two Austrian multiple sclerosis (MS) centres. Participants This research included 67 pwMS, of whom 18 pwMS (including two patient representatives and five MS support group leaders/members) and an additional three family members served as stakeholders. Six neurologists and six physiotherapists, each with >5 years of experience in treating pwMS were interviewed. Intervention Stakeholders actively participated as members of study advisory, project steering and research groups. Researcher-supported peer-to-peer focus groups and individual interviews, conducted in three stages, gathered information on musical preferences and exercise needs. We co-developed, co-evaluated and co-adapted the music-supported exercise programme with the stakeholders. Involvement levels were measured using the Participation Check and Patient Public Involvement (PPI) Assessment Survey, self-efficacy with the Unidimensional Self-Efficacy Scale for Multiple Sclerosis and emotional states with the Self-Assessment Manikin. Results We identified four themes through reflexive thematic analysis: (1) engagement; (2) ease; (3) autonomy; (4) musical meaning. Integration of qualitative and quantitative components highlighted the success of PPI activities: (a) 148 co-created, free videos are publicly available; (b) four videos provide expert interviews with general information, while 144 offer music-supported exercises tailored to pwMS with mild to severe disability; (c) patients found the videos relevant, feasible and usable in interviews and focus groups; (d) ‘easy’ category exercises (seated or lying) are suitable for severely affected pwMS; (e) stakeholders felt included, respected and heard, as shown by quantitative PPI assessments. Conclusions Stakeholders were essential in identifying key aspects, preferences and constraints early on. Their feedback on music and exercise shaped the project. This study transformed our approach to exercise for pwMS. Future studies are required to evaluate the programme’s efficacy. Trial registration number DRKS00027979.
- 7 August 2024
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 30 (9) , 1128-1138
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis—Evidence for applying a rebaselining concept
Background: Employing a rebaselining concept may reduce noise in retinal layer thinning measured by optical coherence tomography (OCT). Methods: From an ongoing prospective observational study, we included patients with relapsing multiple sclerosis (RMS), who had OCT scans at disease-modifying treatment (DMT) start (baseline), 6–12 months after baseline (rebaseline), and ⩾12 months after rebaseline. Mean annualized percent loss (aL) rates (%/year) were calculated both from baseline and rebaseline for peripapillary-retinal-nerve-fiber-layer (aLpRNFLbaseline/aLpRNFLrebaseline) and macular-ganglion-cell-plus-inner-plexiform-layer (aLGCIPLbaseline/aLGCIPLrebaseline) by mixed-effects linear regression models. Results: We included 173 RMS patients (mean age 31.7 years (SD 8.8), 72.8% female, median disease duration 15 months (12-94) median baseline-to-last-follow-up-interval 37 months (18-71); 56.6% moderately effective DMT (M-DMT), 43.4% highly effective DMT (HE-DMT)). Both mean aLpRNFLbaseline and aLGCIPLbaseline significantly increased in association with relapse (0.51% and 0.26% per relapse, p < 0.001, respectively) and disability worsening (1.10% and 0.48%, p < 0.001, respectively) before baseline, but not with DMT class. Contrarily, neither aLpRNFLrebaseline nor aLGCIPLrebaseline was dependent on relapse or disability worsening before baseline, while HE-DMT significantly lowered aLpRNFLrebaseline (by 0.31%, p < 0.001) and aLGCIPLrebaseline (0.25%, p < 0.001) compared with M-DMT. Conclusions: Applying a rebaselining concept significantly improves differentiation of DMT effects on retinal layer thinning by avoiding carry-over confounding from previous disease activity.
- 7 August 2024
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 30 (9) , 1128-1138
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis—Evidence for applying a rebaselining concept
Background: Employing a rebaselining concept may reduce noise in retinal layer thinning measured by optical coherence tomography (OCT). Methods: From an ongoing prospective observational study, we included patients with relapsing multiple sclerosis (RMS), who had OCT scans at disease-modifying treatment (DMT) start (baseline), 6–12 months after baseline (rebaseline), and ⩾12 months after rebaseline. Mean annualized percent loss (aL) rates (%/year) were calculated both from baseline and rebaseline for peripapillary-retinal-nerve-fiber-layer (aLpRNFLbaseline/aLpRNFLrebaseline) and macular-ganglion-cell-plus-inner-plexiform-layer (aLGCIPLbaseline/aLGCIPLrebaseline) by mixed-effects linear regression models. Results: We included 173 RMS patients (mean age 31.7 years (SD 8.8), 72.8% female, median disease duration 15 months (12-94) median baseline-to-last-follow-up-interval 37 months (18-71); 56.6% moderately effective DMT (M-DMT), 43.4% highly effective DMT (HE-DMT)). Both mean aLpRNFLbaseline and aLGCIPLbaseline significantly increased in association with relapse (0.51% and 0.26% per relapse, p < 0.001, respectively) and disability worsening (1.10% and 0.48%, p < 0.001, respectively) before baseline, but not with DMT class. Contrarily, neither aLpRNFLrebaseline nor aLGCIPLrebaseline was dependent on relapse or disability worsening before baseline, while HE-DMT significantly lowered aLpRNFLrebaseline (by 0.31%, p < 0.001) and aLGCIPLrebaseline (0.25%, p < 0.001) compared with M-DMT. Conclusions: Applying a rebaselining concept significantly improves differentiation of DMT effects on retinal layer thinning by avoiding carry-over confounding from previous disease activity.
- Open Access
- 5 August 2021
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (10) , 1033-1043
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
In the last century, several pandemics were caused by various influenza virus subtypes, with the Spanish influenza of 1918–1920 being the most severe.1 Coronaviruses were first described in humans in the 1960s, and since then seven human pathogenic coronaviruses have been described.2 The first severe outbreak was in 2002 with the severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in 2012.3 The current COVID-19 pandemic, which broke out in Wuhan, China, in late 2019, is caused by the highly transmissible RNA virus SARS-CoV-2.4 As of 11 June 2021, 174 439 909 COVID-19 cases and 3 768 987 deaths have been reported worldwide, according to the WHO Dashboard.5
- 5 August 2021
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (10) , 1033-1043
Open AccessVaccination and multiple sclerosis in the era of the COVID-19 pandemic
In the last century, several pandemics were caused by various influenza virus subtypes, with the Spanish influenza of 1918–1920 being the most severe.1 Coronaviruses were first described in humans in the 1960s, and since then seven human pathogenic coronaviruses have been described.2 The first severe outbreak was in 2002 with the severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in 2012.3 The current COVID-19 pandemic, which broke out in Wuhan, China, in late 2019, is caused by the highly transmissible RNA virus SARS-CoV-2.4 As of 11 June 2021, 174 439 909 COVID-19 cases and 3 768 987 deaths have been reported worldwide, according to the WHO Dashboard.5
- Open Access
- 7 July 2021
- Published by Springer Nature in Der Nervenarzt
- Vol. 92 (12) , 1276-1282
Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen
Zusammenfassung: Die aktuelle COVID-19-Pandemie stellt eine weltweite Gesundheitskrise dar. Nicht zuletzt mit dem Aufkommen diverser Virusmutationen entstehen insbesondere für das Gesundheitswesen laufend neue Herausforderungen. Angesichts der Vielfalt an immunmodulatorischen und immunsuppressiven Therapien für die Multiple Sklerose (MS) sowie der enormen Entwicklungen im Bereich der Vakzinenherstellung besteht ein hoher Informationsbedarf für Menschen mit MS. Ziel dieser Arbeit ist es daher, einen Überblick über MS und COVID-19 sowie die damit einhergehenden Implikationen für MS-Patienten, insbesondere das Impfwesen betreffend, aufzuarbeiten und entsprechende Empfehlungen auszusprechen.
- 7 July 2021
- Published by Springer Nature in Der Nervenarzt
- Vol. 92 (12) , 1276-1282
Open AccessDie Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen
Zusammenfassung: Die aktuelle COVID-19-Pandemie stellt eine weltweite Gesundheitskrise dar. Nicht zuletzt mit dem Aufkommen diverser Virusmutationen entstehen insbesondere für das Gesundheitswesen laufend neue Herausforderungen. Angesichts der Vielfalt an immunmodulatorischen und immunsuppressiven Therapien für die Multiple Sklerose (MS) sowie der enormen Entwicklungen im Bereich der Vakzinenherstellung besteht ein hoher Informationsbedarf für Menschen mit MS. Ziel dieser Arbeit ist es daher, einen Überblick über MS und COVID-19 sowie die damit einhergehenden Implikationen für MS-Patienten, insbesondere das Impfwesen betreffend, aufzuarbeiten und entsprechende Empfehlungen auszusprechen.